in 2014 reported the pH-sensitive cationic (YSK05) liposomal siRNA nanoparticle (MEND) modified with cRGD for tumor endothelial cells (TECs) gene silencing, and for VEGF as an anti-angiogenic therapy (155). This evidence concerns the gene VEGFA and neoplasm.